Hu X - Search Results

1

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.

Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, Tong Z, Li H, Zhang Q, Sun T, Wang X, Yin Y, Cheng Y, Li W, Gu Y, Chen Q, Liu J, Cheng J, Geng C, Qin S, Wang S, Lu J, Shen K, Liu Q, Wang X, Wang H, Luo T, Yang J, Wu Y, Yu Z, Zhu X, Chen C, Zou J; PHOEBE Investigators. Xu B, et al. Among authors: hu x. Lancet Oncol. 2021 Mar;22(3):351-360. doi: 10.1016/S1470-2045(20)30702-6. Epub 2021 Feb 11. Lancet Oncol. 2021. PMID: 33581774 Clinical Trial.

2

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.

Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, Zhang Q, Wang X, Feng J, Pang D, Fan M, Li J, Wang B, Wang Z, Zhang Q, Sun S, Liao C. Hu X, et al. Int J Cancer. 2014 Oct 15;135(8):1961-9. doi: 10.1002/ijc.28829. Epub 2014 Mar 20. Int J Cancer. 2014. PMID: 24604288 Free article. Clinical Trial.

3

Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.

Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, Tong Z, Wang S, Li J, Wang Z, Wang B, Chen X, Yu H. Hu X, et al. Among authors: hu w. BMC Cancer. 2014 Nov 7;14:820. doi: 10.1186/1471-2407-14-820. BMC Cancer. 2014. PMID: 25376790 Free PMC article. Clinical Trial.

4

National consensus in China on diagnosis and treatment of patients with advanced breast cancer.

Xu B, Hu X, Jiang Z, Li H, Chen J, Cui S, Li Q, Liao N, Liu D, Liu J, Lu J, Shen K, Sun T, Teng Y, Tong Z, Wang S, Wang X, Wang X, Wang Y, Wu J, Yuan P, Zhang P, Zhang Q, Zheng H, Pang D, Ren G, Shao Z, Shen Z, Song E, Song S. Xu B, et al. Among authors: hu x. Ann Transl Med. 2015 Oct;3(17):242. doi: 10.3978/j.issn.2305-5839.2015.09.47. Ann Transl Med. 2015. PMID: 26605288 Free PMC article. Review.

5

Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.

Xu B, Hu X, Zheng H, Wang X, Zhang Q, Cui S, Liu D, Liao N, Luo R, Sun Q, Yu S. Xu B, et al. Among authors: hu x. Oncotarget. 2016 Aug 2;7(31):50643-50655. doi: 10.18632/oncotarget.9331. Oncotarget. 2016. PMID: 27276706 Free PMC article.

6

Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies.

Xu B, Shao Z, Wang S, Jiang Z, Hu X, Zhang X, Li X, Liu J, Li M, Wang S. Xu B, et al. Among authors: hu x. Chin J Cancer Res. 2018 Jun;30(3):327-339. doi: 10.21147/j.issn.1000-9604.2018.03.05. Chin J Cancer Res. 2018. PMID: 30046227 Free PMC article.

7

Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.

Xie Y, Li Y, Zhang Y, Zhang S, Li W, Guan X, Zhao Y, Gong C, Hu X, Zhang J, Cao E, Wang L, Ge R, Wang B. Xie Y, et al. Among authors: hu x. Clin Breast Cancer. 2019 Jun;19(3):e452-e458. doi: 10.1016/j.clbc.2019.01.015. Epub 2019 Feb 7. Clin Breast Cancer. 2019. PMID: 30846408 Free article.

8

Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.

Yuan P, Hu X, Sun T, Li W, Zhang Q, Cui S, Cheng Y, Ouyang Q, Wang X, Chen Z, Hiraiwa M, Saito K, Funasaka S, Xu B. Yuan P, et al. Among authors: hu x. Eur J Cancer. 2019 May;112:57-65. doi: 10.1016/j.ejca.2019.02.002. Epub 2019 Mar 29. Eur J Cancer. 2019. PMID: 30928806 Free article. Clinical Trial.

9

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, Tong Z, Cheng Y, Pan Y, Sun Y, Wang H, Ouyang T, Gu K, Feng J, Wang X, Wang S, Liu T, Gao J, Cristofanilli M, Ning Z, Lu X. Jiang Z, et al. Among authors: hu x. Lancet Oncol. 2019 Jun;20(6):806-815. doi: 10.1016/S1470-2045(19)30164-0. Epub 2019 Apr 27. Lancet Oncol. 2019. PMID: 31036468 Clinical Trial.

10

A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients.

Wang T, Wu B, Hu X, Liu J, Zhang T, Li F, Sun B, Cai L, Li X, Chen Z, Yang Q, Jiang Z. Wang T, et al. Among authors: hu x. Ann Transl Med. 2019 May;7(9):196. doi: 10.21037/atm.2019.04.10. Ann Transl Med. 2019. PMID: 31205914 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32,297 results

Search Page